Home > Insider Trading > Filing (0000886163-18-000132)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
886163	Ligand Pharmaceuticals Inc	LGND	Pharmaceutical Preparations (2834)	770160744

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1392266	S Charles Berkman	3911 Sorrento Valley Boulevard, Ste 110 San Diego CA 92121	Svp, Gen. Counsel & Secretary	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-09-04	469	$21.92	28,232	No	4	M	Direct
Common Stock	Acquisiton	2018-09-04	5,985	$74.42	34,217	No	4	M	Direct
Common Stock	Acquisiton	2018-09-04	7,077	$56.26	41,294	No	4	M	Direct
Common Stock	Acquisiton	2018-09-04	5,886	$85.79	47,180	No	4	M	Direct
Common Stock	Disposition	2018-09-04	19,417	$254.99	27,763	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2018-09-04	7,077	$0.00	7,077	$56.26
Common Stock	Employee Stock Option (right to buy)	Disposition	2018-09-04	5,985	$0.00	5,985	$74.42
Common Stock	Employee Stock Option (right to buy)	Disposition	2018-09-04	5,886	$0.00	5,886	$85.79
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2018-09-04	469	$0.00	469	$21.92

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,292	2025-02-10	No	4	M	Direct
1,931	2024-02-12	No	4	M	Direct
4,577	2026-02-11	No	4	M	Direct
0	2023-02-15	No	4	M	Direct

Footnotes

The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.85 to $256.59, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/10/15.
Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/12/14.
Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/11/16.
Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/15/13.